April 6, 2020

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✔ **National Stock Exchange of India Ltd.,**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards launch by the Company of Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg. The Company's alliance partner Concord Biotech Limited had received an approval from the U.S. FDA earlier.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For LUPIN LIMITED

R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)

Encl- : a/a.

Press Release

BSE: 500257	NSE: LUPIN	REUTERS: LUPIN.BO	BLOOMBERG: LPCIN

Lupin launches Mycophenolic Acid Delayed-Release Tablets USP

Mumbai, Baltimore, April 06, 2020: Pharma major Lupin Limited (Lupin) announced the launch of Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg. Lupin's alliance partner Concord Biotech Limited (Concord) had received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, is the generic equivalent of Myfortic® Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation, and are indicated for:

- Prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant.
- Use in combination with cyclosporine and corticosteroids.

Mycophenolic Acid Delayed-Release Tablets USP (RLD: Myfortic®) had an annual sales of approximately USD 156 million in the U.S. (IQVIA MAT February 2020).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.
Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/
Facebook: www.facebook.com/LupinWorld/

For further information or queries please contact –

Arvind Bothra Head – Investor Relations and Corporate Communications Email: arvindbothra@lupin.com Tel: +91 22 6640 8237	**Manjira Sharma** General Manager – Corporate Communications Email: manjirasharma@lupin.com Tel: +91 22 6640 2532

*Safe Harbor Statement

Myfortic® is a registered trademark of Novartis AG Corporation Switzerland